CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 100 enrolled / 100 target
Drug / intervention
Diuretic +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05174312
NCT05174312N/ACompletedMonitor (2.1/mo)Completion was 17mo ago
CompareCT.gov

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS) - FASTR Trial

Reprieve Cardiovascular, Inc·interventional·Posted Dec 30, 2021·Updated Jun 23, 2026

In Brief

A clinical study evaluating Reprieve Decongestion Management System and Diuretic for Acute Decompensated Heart Failure. Completed, enrolled 100 participants across 16 sites.

Signals

Enrolling slower than its timeline implies

Detailed Summary

The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve DMS can more efficiently decongest ADHF patients in comparison to Control Therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Decompensated Heart Failure
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedDec 30, 2021
Enrollment StartJul 11, 2022
Primary CompletionJan 10, 2025
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 4.5 years ago

Arms & Interventions

Reprieve Decongestion Management Systemexperimental

Subjects randomized to Reprieve System will receive personalized and optimized diuretic and saline infusion using the study device during the course of the treatment.

Device: Reprieve Decongestion Management System
Optimal Diuretic Therapyactive_comparator

Sites will consider best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC) for patients randomized to control arm of the trial.

Drug: Diuretic

Interventions

Reprieve Decongestion Management Systemdevice

The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.

Diureticdrug

Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).